Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.

Por Shernan G Holtan, Preston D Steen, Nathan R Foster, Charles Erlichman, Fabiola Medeiros, Matthew M Ames, Stephanie L Safgren, David L Graham, Robert J Behrens, Matthew P Goetz
Publicado em 2012-01-01